Acutus Medical downgraded by JP Morgan
$AFIB
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
JP Morgan downgraded Acutus Medical from Neutral to Underweight
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/20/2022 | Buy → Neutral | BTIG | |
| 1/14/2022 | $10.00 → $3.00 | Buy → Hold | Canaccord Genuity |
| 11/15/2021 | Neutral → Underweight | JP Morgan | |
| 11/12/2021 | Neutral → Underweight | JP Morgan | |
| 11/12/2021 | $18.00 → $10.00 | Buy | Canaccord Genuity |
| 10/22/2021 | $10.00 | Neutral | Goldman |
| 7/15/2021 | $11.00 → $18.00 | Hold → Buy | Canaccord Genuity |
CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023. About Acutus Medical, Inc.Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California. Investor Contact:Chad HollisterAcutus
CARLSBAD, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced today that it will release its third quarter 2023 financial results on Monday, November 13, 2023. In conjunction with the release, Acutus will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon registering, each participant will receive an email confirmation with dial-in numbers and a
CARLSBAD, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the second quarter of 2023. Recent Highlights: Second quarter revenue of $5.3 million grew 30% year-over-year, reflecting strong procedure volume growth and improved capital salesQuarterly AcQMap procedure volumes set a new record and increased 21% compared to the second quarter of 2022Received FDA 510K clearance for AcQMap 9 next generation software platform featuring advanced algorithms and automation to improve diagnostic capabil
SC 13G - Acutus Medical, Inc. (0001522860) (Subject)
SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)
SC 13G/A - Acutus Medical, Inc. (0001522860) (Subject)
BTIG downgraded Acutus Medical from Buy to Neutral
Canaccord Genuity downgraded Acutus Medical from Buy to Hold and set a new price target of $3.00 from $10.00 previously
JP Morgan downgraded Acutus Medical from Neutral to Underweight
8-K - Acutus Medical, Inc. (0001522860) (Filer)
10-Q - Acutus Medical, Inc. (0001522860) (Filer)
8-K - Acutus Medical, Inc. (0001522860) (Filer)
CARLSBAD, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced preliminary unaudited results for the fourth quarter and full year 2022. The Company also announced the appointment of Takeo Mukai as Senior Vice President & Chief Financial Officer. Preliminary Unaudited Fourth Quarter and Full Year 2022 ResultsThe Company expects fourth quarter 2022 revenue of approximately $4.7-$4.9 million compared to $4.4 million in the fourth quarter of 2021. Year-over-year growth was driven by an increase in commercial AcQMap pr
SAN JOSE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- BrightInsight, Inc., provider of the leading global platform for biopharma and medtech regulated digital health solutions, announced today the appointment of Tamara Elias, M.D., Senior Vice President at Nuance, and Scott Huennekens, executive chairperson at Hyperfine, Wondr Medical, Acutus Medical and Envista Holdings Corporation, to the BrightInsight Advisory Council. Dr. Elias and Huennekens bring deep and complimentary experience to this group of industry experts, who work with BrightInsight leadership to advance the company's vision to transform patient outcomes globally through the power of digital technology. Dr. Elias and Huennek
CARLSBAD, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Acutus Medical ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the appointment of Niamh Pellegrini to the Company's Board of Directors, effective August 10, 2021. Ms. Pellegrini has over 20 years of experience in the healthcare industry and, since July 2019, has served as the Chief Commercial Officer of Nevro, Inc., a medical device company dedicated to helping patients suffering from chronic pain achieve lasting relief. "Niamh is an experienced and proven executive and commercial leader," said Vince Burgess, President and CEO of Acutu
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
4 - Acutus Medical, Inc. (0001522860) (Issuer)
CARLSBAD, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the second quarter and year-to-date of 2024. Recent Highlights: Second quarter revenue from Continuing Operations of $4.1 million grew 172% year-over-year, from $1.5 million in the same quarter last year.Operating expenses for continuing operations were $2.2 million, a reduction of 47% compared to the same period last year.Recorded $2.9 million in gain on sale of business, an increase of 38% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $13.3 million as of June 30, 2024. Second Quarter 20
CARLSBAD, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (OTC:AFIB) today reported results for the first quarter of 2024. Recent Highlights: First quarter revenue from Continuing Operations of $3.6 million grew 192% year-over-year, from $1.2 million in the same quarter last year..Operating expenses for continuing operations were $3.3 million, a reduction of 38% compared to the same period last year.Recorded $2.8 million in gain on sale of business, an increase of 131% compared to the same period last year.Cash, cash equivalents, marketable securities and restricted cash were $20.0 million as of March 31, 2024. First Quarter 2024 Financial
CARLSBAD, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB) today reported results for the fourth quarter and full year ended December 31,2023. Recent Highlights: Announced strategic realignment of resources and corporate restructuring on November 8, 2023 with the objective of optimizing financial position and maximizing free cash flow.The Continuing Operations focuses on the implementation of the business model to shift to solely support the manufacturing and distribution of Medtronic's left-heart access product portfolio.Discontinued Operations relates to the Company's mapping and ablation business that was wound down as part of t
Shares of Upstart Holdings, Inc. (NASDAQ:UPST) fell sharply during Wednesday's session after the company reported first-quarter financial results and issued second-quarter revenue guidance below estimates. Upstart reported first-quarter revenue of $128 million, which beat the consensus estimate of $124.867 million, according to Benzinga Pro. Upstart expects second-quarter revenue of approximately $125 million versus estimates of $140.83 million. The company anticipates a second-quarter adjusted EBITDA loss of approximately $25 million. Upstart shares dipped 10.3% to $21.96 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Reborn Coffee, In
Shares of RingCentral, Inc. (NYSE:RNG) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and raised its FY24 guidance. RingCentral posted adjusted earnings of 87 cents per share, beating market estimates of 80 cents per share. The company's quarterly sales came in at $584.211 million, topping expectations of $578.167 million, according to data from Benzinga Pro. RingCentral shares jumped 13.4% to $34.00 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Repare Therapeutics Inc. (NASDAQ:RPTX) gained 31.1% to $4.30 in pre-market trading after the company posted better-t
Gainers Nuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday's regular session. The company's market cap stands at $4.1 million. As per the news, the Q1 earnings report came out today. Bioventus (NASDAQ:BVS) stock moved upwards by 28.87% to $5.16. The market value of their outstanding shares is at $329.0 million. The company's, Q1 earnings came out today. Design Therapeutics (NASDAQ:DSGN) stock rose 28.49% to $4.69. The market value of their outstanding shares is at $264.9 million. Acutus Medical (NASDAQ:AFIB) stock moved upwards by 24.11% to $0.13. The company's market cap stands at $3.9 million. Oragenics (AMEX:OGEN) shares moved upwards by 22.78% to $1.33. The market valu